Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jessica, Guenzle"'
Autor:
Katharina Joechle, Huda Jumaa, Kerstin Thriene, Claus Hellerbrand, Birte Kulemann, Stefan Fichtner-Feigl, Sven A. Lang, Jessica Guenzle
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2022)
Cholangiocarcinoma (CCA) is a rare but highly aggressive tumor entity for which systemic therapies only showed limited efficacy so far. As OSI-027—a dual kinase inhibitor targeting both mTOR complexes, mTORC1 and mTORC2 - showed improved anti-cance
Externí odkaz:
https://doaj.org/article/48299dcc90324eb395cc177ebe8665e2
Autor:
Katharina M. Schmidt, Peter Dietrich, Christina Hackl, Jessica Guenzle, Peter Bronsert, Christine Wagner, Stefan Fichtner-Feigl, Hans J. Schlitt, Edward K. Geissler, Claus Hellerbrand, Sven A. Lang
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 12, Pp 1198-1208 (2018)
Mammalian target of rapamycin complex 2 (mTORC2) with its pivotal component rapamycin-insensitive companion of mTOR (RICTOR) is the major regulator of AKT phosphorylation and is increasingly implicated in tumor growth and progression. In cutaneous me
Externí odkaz:
https://doaj.org/article/20c6861415594974be5d32007e992bfb
Autor:
Jessica Guenzle, Harue Akasaka, Katharina Joechle, Wilfried Reichardt, Aina Venkatasamy, Jens Hoeppner, Claus Hellerbrand, Stefan Fichtner-Feigl, Sven A. Lang
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 1, p 30 (2020)
Despite recent advances in therapy, liver metastasis from melanoma is still associated with poor prognosis. Although targeting the mTOR signaling pathway exerts potent anti-tumor activity, little is known about specific mTORC2 inhibition regarding li
Externí odkaz:
https://doaj.org/article/7e321b5aadb8416f8c83793d9d50239c
Autor:
Katharina Joechle, Jessica Guenzle, Stefan Utzolino, Stefan Fichtner-Feigl, Lampros Kousoulas
Publikováno v:
Langenbeck's Archives of Surgery. 407:1173-1182
Purpose Although Ogilvie’s syndrome was first described about 70 years ago, its etiology and pathogenesis are still not fully understood. But more importantly, it is also not clear when to approach which therapeutic strategy. Methods Patients who w
Autor:
Lukas M. Braun, Simon Lagies, Jessica Guenzle, Stefan Fichtner-Feigl, Uwe A. Wittel, Bernd Kammerer
Publikováno v:
Cells, Vol 9, Iss 5, p 1251 (2020)
Pancreatic ductal adenocarcinoma (PDAC) correlates with high mortality and is about to become one of the major reasons for cancer-related mortality in the next decades. One reason for that high mortality is the limited availability of effective chemo
Externí odkaz:
https://doaj.org/article/396e27d8acde40dc9b20bac43b53086f
Autor:
Max Heckler, Nadja Osterberg, Jessica Guenzle, Nina Kristin Thiede-Stan, Wilfried Reichardt, Claudia Weidensteiner, Joseph E Saavedra, Astrid Weyerbrock
Publikováno v:
Tumor Biology, Vol 39 (2017)
As a potent radiosensitizer nitric oxide (NO) may be a putative adjuvant in the treatment of malignant gliomas which are known for their radio- and chemoresistance. The NO donor prodrug JS-K (O2-(2.4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-y
Externí odkaz:
https://doaj.org/article/9208c2cddd6745f8b8556917ad7999ed
Autor:
Kim Grebe, Martha B. Pitman, Birte Kulemann, Jessica Guenzle, Jasmina Kuvendjiska, Sylvia Timme, Verena Martini, Claudia Schmoor, Jens Hoeppner, Clara Braun, Torben Glatz, Stefan Fichtner-Feigl
Publikováno v:
Anticancer Research. 40:5679-5685
Background/aim The presence of circulating tumor cells (CTC) has been reported to have an impact on prognosis in different tumor entities. Little is known about CTC morphology and heterogeneity. Patients and methods In a multicenter setting, pre-ther
Autor:
Katharina, Joechle, Jessica, Guenzle, Stefan, Utzolino, Stefan, Fichtner-Feigl, Lampros, Kousoulas
Publikováno v:
Langenbeck's archives of surgery. 407(3)
Although Ogilvie's syndrome was first described about 70 years ago, its etiology and pathogenesis are still not fully understood. But more importantly, it is also not clear when to approach which therapeutic strategy.Patients who were diagnosed with
Publikováno v:
Molecular Neurobiology. 56:6046-6055
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with a high recurrence rate and a median survival of about 16 months even with multimodal therapy. Novel experimental strategies against malignant gliomas include cyclooxygenase (COX) i
Autor:
Katharina Joechle, Jessica Guenzle, Thorsten Cramer, Claus Hellerbrand, Pavel Strnad, Sven A. Lang, Ulf P. Neumann
Publikováno v:
World journal of gastrointestinal oncology 13(11), 1632-1647 (2021). doi:10.4251/wjgo.v13.i11.1632
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology
World journal of gastrointestinal oncology 13(11), 1632-1647 (2021). doi:10.4251/wjgo.v13.i11.1632
Published by Beijing Baishideng BioMed Scientific Co., Beijing
Published by Beijing Baishideng BioMed Scientific Co., Beijing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e0f99e44cf0b3842a5c63abe81f3fe9